1. WHO. Cardiovascular diseases, W.H. Organization 2022.
2.
Navas LE, Carnero A. Nicotinamide adenine dinucleotide (NAD) metabolism as a relevant target in cancer. Cells 2022; 11: 2627.
3.
Griffiths HBS, Williams C, King SJ, Allison SJ. Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target. Biochem Soc Trans 2020; 48: 733-774.
4.
Anu RI, Shiu KK, Khan KH. The immunomodulatory role of IDO1-Kynurenine-NAD(+) pathway in switching cold tumor microenvironment in PDAC. Front Oncol 2023; 13: 1142838.
5.
Orhan C, Sahin E, Tuzcu M, Sahin N, Celik A, Ojalvo SP, Sylla S, Komorowski JR, Sahin K. Nicotinamide riboside and phycocyanin oligopeptides affect stress susceptibility in chronic corticosterone-exposed rats. Antioxidants (Basel) 2023; 12: 1849.
6.
Dow LF, Case AM, Paustian MP, Pinkerton BR, Simeon P, Trippier PC. The evolution of small molecule enzyme activators. RSC Med Chem 2023; 14: 2206-2230.
7.
Wang S, Jiang W, jin X, Qi Q, Liang Q. Genetically encoded ATP and NAD(P)H biosensors: potential tools in metabolic engineering. Crit Rev Biotechnol 2023; 43: 1211-1225.
8.
Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Nicotinamide adenine dinucleotide in aging biology: potential applications and many unknowns. Endocr Rev 2023; 44: 1047-1073.
9.
Jeje O, Otun S, Aloke C, Achilonu I. Exploring NAD+ metabolism and NNAT: Insights from structure, function, and computational modeling. Biochimie 2024; 220: 84-98.
10.
Almeida KH, Avalos-Irving L, Berardinelli S, Chauvin K, Yanez S. Novel carbon skeletons activate human NicotinAMide Phosphoribosyl Transferase (NAMPT) enzyme in biochemical assay. PLoS One 2023; 18: e0283428.
11.
Sauve AA, Wang Q, Zhang N, Kang S, Rathmann A, Yang Y. Triple-isotope tracing for pathway discernment of NMN-induced NAD+ biosynthesis in whole mice. Int J Mol Sci 2023; 24: 11114.
12.
Marzook H, Gupta A, Tomar D, Saleh MA, Patil K, Semreen MH, Hamoudi R, Soares NC, Qaisar R, Ahmad F. Nicotinamide riboside kinase-2 regulates metabolic adaptation in the ischemic heart. J Mol Med 2023; 101: 311-326.
13.
Harden A, Young WJ, Martin CJ. The alcoholic ferment of yeast-juice. Proc R Soc London B 1906; 77: 405-420.
14.
Guo C, Huang Q, Wang Y, Yao Y, Li J, Chen J, Wu M, Zhang Z, Mingyao E, Qi H, Ji P, Liu Q, Zhao D, Su H, Qi W, Li X. Therapeutic application of natural products: NAD+ metabolism as potential target. Phytomedicine 2023; 114: 154768.
15.
Campagna R, Vignini A. NAD+ homeostasis and NAD+-consuming enzymes: implications for vascular health. Antioxidants 2023; 12: 376.
16.
Zhu X, Li J, Wang H, Gasior FM, Lee C, Lin S, Justice CN, O’Donnell JM, Vanden Hoek TL. Nicotinamide restores tissue NAD+ and improves survival in rodent models of cardiac arrest. PLoS One 2023; 18: e0291598.
17.
Helman T, Braidy N. Importance of NAD+ anabolism in metabolic, cardiovascular and neurodegenerative disorders. Drugs Aging 2023; 40: 33-48.
18.
Wang Y, Gaul DS, Pahla J, Dahlby T, Dietrich E, Osto E, Gariani K, Costanti- no S, Paneni F, Winnik S, Stein S, Ruschitzka F, Auwerx J, Matter CM. High dose NAD+ boosting as pan-sirtuin activation increases atherosclerotic plaques and systemic inflammation in Apoe knockout mice. Eur Heart J 2023; 44 (Suppl 2).
19.
Visnagri A, Oexner RR, Kmiotek-Wasylewska K, Zhang M, Zoccarato A, Shah AM. Nicotinamide adenosine dinucleotide phosphate oxidase-mediated signaling in cardiac remodeling. Antioxid Redox Signal 2023; 38: 371-387.
20.
Pencina KM, Valderrabano R, Wipper B, Orkaby AR, Reid KF, Storer T, Lin AP, Merugumala S, Wilson L, Latham N, Ghattas-Puylara C, Ozimek NE, Cheng M, Bhargava A, Memish-Beleva Y, Lawney B, Lavu S, Swain PM, Apte RS, Sin- clair DA, Livingston D, Bhasin S. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults: a physiologic study. J Clin Endocrinol Metabol 2023; 108: 1968-1980.
21.
Lee SY, Kuo YH, Du CX, Huang CW, Ku HC. A novel caffeic acid derivative prevents angiotensin II-induced cardiac remodeling. Biomed Pharmacother 2023; 162: 114709.
22.
Tannous C, Ghali R, Karoui A, Habeichi NJ, Amin G, Booz GW, Mericskay M, Refaat M, Zouein FA. Nicotinamide riboside supplementation restores myocardial nicotinamide adenine dinucleotide levels, improves survival, and promotes protective environment post myocardial infarction. Cardiovasc Drugs Ther 2023; doi: 10.1007/s10557-023-07525-1.
23.
Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep 2023; 13: 2786.
24.
Pool L, Knops P, Manintveld OC, Brugts JJ, Theuns DAMJ, Brundel BJJM, de Groot NMS. The HF-AF ENERGY Trial: nicotinamide riboside for the treatment of atrial fibrillation in heart failure patients. Cardiovasc Drugs Ther 2023; 37: 1243-1248.
25.
Xiao Y, Wang Q, Preckel B, Hollmann MW, Weber NC, Schomakers BV, Van Weeghel M, Zuurbier C. Nicotinamide riboside cardioprotection is mediated through glycolysis activation. Eur Heart J 2023; 44 (Suppl 2).
26.
Marques SM, Melo MR, Zoccal DB, Menani JV, Colombari DSA, Ferreira- Neto ML, Xavier CH, Colombari E, Pedrino GR. Acute inhibition of nicotinamide adenine dinucleotide phosphate oxidase in the commissural nucleus of the solitary tract reduces arterial pressure and renal sympathetic nerve activity in renovascular hypertension. J Hypertens 2023; 41: 1634-1644.
27.
Zarà M, Baggiano A, Amadio P, Campodonico J, Gili S, Annoni A, De Dona G, Carerj ML, Cilia F, Formenti A, Fusini L, Banfi C, Gripari P, Tedesco CC, Manci- ni ME, Chiesa M, Maragna R, Marchetti F, Penso M, Tassetti L, Volpe A, Bonomi A, Marenzi G, Pontone G, Barbieri SS. Circulating small extracellular vesicles reflect the severity of myocardial damage in STEMI patients. Biomolecules 2023; 13: 1470.
28.
Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. Nat Rev Cardiol 2023; 20: 754-777.
29.
Nollet EE, Duursma I, Rozenbaum A, Eggelbusch M, Wüst RCI, Schoonvel- de SAC, Michels M, Jansen M, van der Wel NN, Bedi KC, Margulies KB, Nirschl J, Kuster DWD, van der Velden J. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration. Eur Heart J 2023; 44: 1170-1185.
30.
Sequeira V, Batzner A, Maack C. Targeting mitochondria in hypertrophic cardiomyopathy. Eur Heart J 2023; 44: 1186-1188.
31.
Gonçalinho GHF, Kuwabara KL, de Oliveira Faria NF, da Silva Goes MF, Roggerio A, Avakian SD, Strunz CMC, de Padua Mansur A. Sirtuin 1 and vascular function in healthy women and men: a randomized clinical trial comparing the effects of energy restriction and resveratrol. Nutrients 2023; 15: 2949.
32.
Wang L, Guo S, Cao K, Li Z, Li Z, Song M, Wang C, Chen P, Cui Y, Dai X, Feng D, Fu X, He J, Xu Y. Glycolysis promotes angiotensin II-induced aortic remodeling through regulating endothelial-to-mesenchymal transition via the corepressor C-terminal binding protein 1. Hypertension 2023; 80: 2627-2640.
33.
Wang S, Zhao H, Lin S, Lv Y, Lin Y, Liu Y, Peng P, Jin H. New therapeutic directions in type II diabetes and its complications: mitochondrial dynamics. Front Endocrinol (Lausanne) 2023; 14: 1230168.
34.
Zhang Y, Zhu W, Wang M, Xi P, Wang H, Tian D. Nicotinamide mononucleotide alters body composition and ameliorates metabolic disorders induced by a high-fat diet. IUBMB Life 2023; 75: 548-562.
35.
Mohammad A, Babiker F, Al-Bader M. Effects of apocynin, a NADPH oxidase inhibitor, in the protection of the heart from ischemia/reperfusion injury. Pharmaceuticals 2023; 16: 492.
36.
Huang Q, Chen Y. NADPH oxidase 4 contributes to oxidative stress in a mouse model of myocardial infarction. Physiol Res 2023; 72: 177-186.
37.
Wu Y, Pei Z, Qu P. NAD(+)-a hub of energy metabolism in heart failure. Int J Med Sci 2024; 21: 369-375.
38.
Sun Y, Chanrasekhar V, Kessinger CW, Tang P, Gao Y, Kamli-Salino S, Nelson K, Delibegovic M, Abel ED, Kontaridis MI. Cardiomyocyte-specific deletion of PTP1B protects against HFD-induced cardiomyopathy through direct regulation of cardiac metabolic signaling. bioRxiv 2023: doi: https://doi.org/2023.05.19.541546.
39.
Xie S, Xu SC, Deng W, Tang Q Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications. Signal Transduct Targeted Ther 2023; 8: 114.
40.
Ouyang Y, Hong Y, Mai C, Yang H, Wu Z, Gao X, Zeng W, Deng X, Liu B, Zhang Y, Fu Q, Huang H, Liu J, Li X. Transcriptome analysis reveals therapeutic potential of NAMPT in protecting against abdominal aortic aneurysm in human and mouse. Bioactive Materials 2024; 34: 17-36.
41.
Wen Z, Jiang L, Yu F, Xu X, Chen M, Xue J, Zhu P, Ying Z, Li Z, Chen T. Single-cell landscape reveals NAMPT mediated macrophage polarization that regulate smooth muscle cell phenotypic switch in pulmonary arterial hypertension. bioRxiv 2023. doi: https://doi.org/2023.07.04.547668.
42.
Opstad TB, Papotti B, Åkra S, Hansen CH, Braathen B, Tønnessen T, Sol- heim S, Seljeflot I. Sirtuin1, not NAMPT, possesses anti-inflammatory effects in epicardial, pericardial and subcutaneous adipose tissue in patients with CHD. J Transl Med 2023; 21: 644.
43.
Liu Y, Wang J, Zhao X, Li W, Liu Y, Li X, Zhao D, Yu J, Ji H, Shao B, Li Z, Wang J, Yang Y, Hao Y, Wu Y, Yuan Y, Du Z. CDR1as promotes arrhythmias in myocardial infarction via targeting the NAMPT-NAD+ pathway. Biomed Pharmacother 2023; 165: 115267.
44.
Yang HB, Yuan W, Li WD, Mao S. Selenium supplementation protects against arsenic-trioxide-induced cardiotoxicity via reducing oxidative stress and inflammation through increasing NAD+ pool. Bioll Trace Element Res 2023; 201: 3941-3950.
45.
Xue X, Miao Y, Wei Z. Nicotinamide adenine dinucleotide metabolism: driving or counterbalancing inflammatory bowel disease? FEBS Letters 2023; 597: 1179-1192.
46.
Eller J, Goyal S, Cambronne XA. Improved yield for the enzymatic synthesis of radiolabeled nicotinamide adenine dinucleotide. ACS Bio Med Chem Au 2023; 3: 46-50.
47.
Zhang Y, Wang Y, Lu S, Zhong R, Liu Z, Zhao Q, Wang C. Nicotinamide phosphoribosyltransferase-elevated NAD+ biosynthesis prevents muscle disuse atrophy by reversing mitochondrial dysfunction. J Cachexia Sarcopenia Muscle 2023; 14: 1003-1018.
48.
Zhou M, Li Y, Che H, sun Y, Wang S, Zhan Y, Cai D, Chen S. Metabolic engineering of Bacillus licheniformis for the bioproduction of nicotinamide riboside from nicotinamide and glucose. ACS Sustainable Chem Eng 2023; 11: 6201-6210.
49.
Kim, M, Kim H, Kang BG, Lee J, Kim T, Lee H, Jung J, Oh MJ, Seo S, Ryu MJ, Sung Y, Lee Y, Yeom J, Han G, Cha SS, Jung H, Kim HS. Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy. Theranostics 2023; 13: 5075-5098.
50.
Winter J, Kunze R, Veit N, Kuerpig S, Meisenheimer M, Kraus D, Glassmann A, Probstmeier R. Targeting of glucose transport and the NAD pathway in neuroendocrine tumor (NET) cells reveals new treatment options. Cancers 2023; 15: 1415.
51.
Navas LE, Blanco-Alcaina E, Suarez-Martinez E, Verdugo-Sivianes EM, Espinosa-Sanchez A, Sanchez-Diaz L, Dominguez-Medina E, Fernandez-Rozadil- la C, Carracedo A, Wu LE, Carnero A. NAD pool as an antitumor target against cancer stem cells in head and neck cancer. J Exp Clin Cancer Res 2023; 42: 55.
52.
Curran CS, Kopp JB. The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease. J Transl Med 2023; 21: 706.
53.
Nomura M, Ohuchi M, Sakamoto Y, Kudo K, Yaku K, Soga T, Sugiura Y, Mori- ta M, Hayashi K, Miyahara S, Sato T, Yamashita Y, Ito S, Kikuchi N, Sato I, Saito R, Yaegashi N, Fukuhara T, Yamada H, Shima H, Nakayama KI, Hirao A, Kawasaki K, Arai Y, Akamatsu S, Tanuma SI, Sato T, Nakagawa T, Tanuma N. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma. Nat Commun 2023; 14: 8095.
54.
Brown J. A content analysis of National African American Reparation Commission’s Reparations plan for older black Americans. Innov Aging 2023; 7 (Suppl 1): 976-977.
55.
Minazzato G, Marangoni E, Fortunato C, Petrelli R, Cappellacci L, Del Bello F, Sorci L, Gasparrini M, Piacente F, Bruzzone S, Raffaelli N. A versatile continuous fluorometric enzymatic assay for targeting nicotinate phosphoribosyltransferase. Molecules 2023; 28: 961.
56.
Chen C, Yan W, Tao M, Fu Y. NAD+ metabolism and immune regulation: new approaches to inflammatory bowel disease therapies. Antioxidants 2023; 12: 1230.
57.
Matsumoto S, Biniecka P, Bellotti A, Duchosal MA, Nahimana A. Nicotinaldehyde, a novel precursor of NAD biosynthesis, abrogates the anti-cancer activity of an NAD-lowering agent in leukemia. Cancers 2023; 15: 787.
58.
Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, Xiao Y, Pham T, Haverty PM, Liederer B, Liang X, Yauch RL, O’Brien T, Bourgon R, Koeppen H, Belmont LD. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin Cancer Res 2013; 19: 6912-6923.
59.
Katsyuba, E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metabol 2020; 2: 9-31.
60.
Braidy N, Sachdev PS. Pharmacology of NAD+boosters. In: Anti-Aging Pharmacology. Koltover VK (ed.). Academic Press 2023; 177-192.
61.
Freeberg KA, Udovich CAC, Martens CR, Seals DR, Craighead DH. Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions. J Gerontol A Biol Sci Med Sci 2023; 78: 2435-2448.
62.
Sharma A, Chabloz S, Lapides RA, Roider E, Ewald CY. Potential synergistic supplementation of NAD+ promoting compounds as a strategy for increasing healthspan. Nutrients 2023; 15: 445.
63.
Luo S, Zhao J, Zheng Y, Chen T, Wang Z. Biosynthesis of nicotinamide mononucleotide: current metabolic engineering strategies, challenges, and prospects. Fermentation 2023; 9: 594.
64.
Carrera-Juliá S, Estrela JM, Zacarés M, Navarro MA, Vega-Bello MJ, de la Rubia Ortí JE, Moreno ML, Drehmer E. Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study. Front Nutr 2023; 10: 1232184.
65.
Zhao X, Kong M, Wang Y, Mao Y, Xu H, He W, He Y, Gu J. Nicotinamide mononucleotide improves the Alzheimer’s disease by regulating intestinal microbiota. Biochem Biophys Res Commun 2023; 670: 27-35.
66.
Song Q, Zhou X, Xu K, Liu S, Zhu X, Yang J. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Adv Nutr 2023; 14: 1416-1435.
67.
Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of -nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience 2023; 45: 29-43.
68.
Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S. MIB-626, an oral formulation of a microcrystalline unique polymorph of -nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci 2022; 78: 90-96.
69.
Xu J, Chen X, Liu S, Wei Z, Xu M, Jiang L, Han X, Peng L, Gu X, Xia T. Nicotinamide mononucleotide pretreatment improves long-term isoflurane anesthesia-induced cognitive impairment in mice. Behav Brain Res 2024; 458: 114738.
70.
Zhang R, Chen S, Wang Z, Ye L, Jiang Y, Li M, Jiang X, Peng H, Guo Z, Chen L, Zhang R, Niu Y, Aschner M, Li D, Chen W. Assessing the effects of nicotinamide mononucleotide supplementation on pulmonary inflammation in male mice subchronically exposed to ambient particulate matter. Environm Health Perspect 2023; 131: 077006.
71.
Feuz MB, Meyer-Ficca ML, Meyer RG. Beyond pellagra – research models and strategies addressing the enduring clinical relevance of NAD deficiency in aging and disease. Cells 2023; 12: 500.
72.
Gawa³ko M, Saljic A, Li N, Abu-Taha I, Jespersen T, Linz D, Nattel S, Heijman J, Fender A, Dobrev D. Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance. Cardiovasc Res 2022; 119: 614-630.
73.
Liu HY, Wang FH, Liang JM, Xiang YY, Liu SH, Zhang SW, Zhu CM, He YL, Zhang CH. Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer. J Cancer Res Clin Oncol 2023; 149: 2743-2756.
74.
Loreto A, Antoniou C, Merlini E, Gilley J, Coleman MP. NMN: the NAD precursor at the intersection between axon degeneration and anti-ageing therapies. Neurosci Res 2023; 197: 18-24.
75.
Musi N. NAD-elevating interventions for cardiometabolic disease. J Clin Endocrinol Metabol 2023; 108: e897-e898.
76.
Han Y, Kim SY. Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics. Exp Mol Med 2023; 55: 1-12.
77.
Stock AJ, Ayyar S, Kashyap A, Wang Y, Yanai H, Starost MF, Tanaka-Yano M, Bodogai M, Sun C, Wang Y, Gong Y, Puligilla C, Fang EF, Bohr VA, Liu Y, Beerman I. Boosting NAD ameliorates hematopoietic impairment linked to short telomeres in vivo. Geroscience 2023; 45: 2213-2228.
78.
Yu Q, Zhao G, Liu J, Peng Y, Xu X, Zhao F, Shi Y, Jin C, Zhang J, Wei B. The role of histone deacetylases in cardiac energy metabolism in heart diseases. Metabolism 2023; 142: 155532.
79.
Napiórkowska-Baran K, Schmidt O, Szymczak B, Lubañski J, Doligalska A, Bartuzi Z. Molecular linkage between immune system disorders and atherosclerosis. Curr Issues Mol Biol 2023; 45: 8780-8815.
80.
Huang Z, Song S, Zhang X, Zeng L, Sun A, Ge J. Metabolic substrates, histone modifications, and heart failure. Biochim Biophys Acta Gene Regul Mech 2023; 1866: 194898.
81.
McKay-Corkum GB, Collins VJ, Yeung C, Ito T, Issaq SH, Holland D, Vulikh K, Zhang Y, Lee U, Lei H, Mendoza A, Shern JF, Yohe ME, Yamamoto K, Wil- son K, Ji J, Karim BO, Thomas CJ, Krishna MC, Neckers LM, Heske CM. Inhibition of NAD+-dependent metabolic processes induces cellular necrosis and tumor regression in rhabdomyosarcoma models. Clin Cancer Res 2023; 29: 4479-4491.
82.
Li X, Yang H, Jin H, Turkez H, Ozturk G, Doganay HL, Zhang C, Nielsen J, Uhlén M, Borén J, Mardinoglu A. The acute effect of different NAD+ precursors included in the combined metabolic activators. Free Radic Biol Med 2023; 205: 77-89.
83.
Waddell J, Khatoon R, Kristian T. Cellular and mitochondrial NAD homeostasis in health and disease. Cells 2023; 12: 1329.
84.
Tribble JR, Hagstrom A, Jusseaume K, Lardner E, Wong RCB, Stalhammar G, Williams PA. NAD salvage pathway machinery expression in normal and glaucomatous retina and optic nerve. Acta Neuropathol Commun 2023; 11: 18.
85.
Wang XZ, Liang SP, Chen X, Wang ZC, Li C, Feng CS, Lu S, He C, Wang YB, Chi GF, Ge PF. TAX1BP1 contributes to deoxypodophyllotoxin-induced glioma cell parthanatos via inducing nuclear translocation of AIF by activation of mitochondrial respiratory chain complex I. Acta Pharmacol Sin 2023; 44: 1906-1919.
86.
Liu, Y, Wang B, Zhu J, Xu X, Zhou B, Yang Y. Single-atom nanozyme with asymmetric electron distribution for tumor catalytic therapy by disrupting tumor redox and energy metabolism homeostasis. Adv Mater 2023; 35: 2208512.
87.
Sharma A, Mahur P, Muthukumaran J, Singh AK, Jain M. Shedding light on structure, function and regulation of human sirtuins: a comprehensive review. 3 Biotech 2022; 13: 29.
88.
Ren C, Yan R, Yuan Z, Yin L, Li H, Ding J, Wu T, Chen R. Maternal exposure to sunlight-irradiated graphene oxide induces neurodegeneration-like symptoms in zebrafish offspring through intergenerational translocation and genomic DNA methylation alterations. Environ Int 2023; 179: 108188.
89.
Luongo TS, Eller JM, Lu MJ, Niere M, Raith F, Perry C, Bornstein MR, Oliphint P, Wang L, McReynolds MR, Migaud ME, Rabinowitz JD, Johnson FB, Johnsson K, Ziegler M, Cambronne XA, Baur JA. SLC25A51 is a mammalian mitochondrial NAD(+) transporter. Nature 2020; 588: 174-179.
90.
Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 2005; 280: 36334-36341.
91.
Mouchiroud L, Houtkooper RH, Auwerx J. NAD metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol 2013; 48: 397-408.
92.
Gasparrini M, Sorci L, Raffaelli N. Enzymology of extracellular NAD metabolism. Cell Mol Life Sci 2021; 78: 3317-3331.
93.
Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 74-78.
94.
Xu CQ, Li J, Liang ZQ, Zhong YL, Zhang ZH, Hu XQ, Cao YB, Chen J. Sirtuins in macrophage immune metabolism: a novel target for cardiovascular disorders. Int J Biol Macromol 2024; 256: 128270.
